Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.

MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
Nature Neuroscience (Impact Factor: 14.98). 01/2000; 2(12):1137-40. DOI: 10.1038/16060
Source: PubMed

ABSTRACT Synaptic dopamine release from embryonic nigral transplants has been monitored in the striatum of a patient with Parkinson's disease using [11C]-raclopride positron emission tomography to measure dopamine D2 receptor occupancy by the endogenous transmitter. In this patient, who had received a transplant in the right putamen 10 years earlier, grafts had restored both basal and drug-induced dopamine release to normal levels. This was associated with sustained, marked clinical benefit and normalized levels of dopamine storage in the grafted putamen. Despite an ongoing disease process, grafted neurons can thus continue for a decade to store and release dopamine and give rise to substantial symptomatic relief.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past two decades, regenerative therapies using stem cell technologies have been developed for various neurological diseases. Although stem cell therapy is an attractive option to reverse neural tissue damage and to recover neurological deficits, it is still under development so as not to show significant treatment effects in clinical settings. In this review, we discuss the scientific and clinical basics of adult neural stem cells (aNSCs), and their current developmental status as cell therapeutics for neurological disease. Compared with other types of stem cells, aNSCs have clinical advantages, such as limited proliferation, inborn differentiation potential into functional neural cells, and no ethical issues. In spite of the merits of aNSCs, difficulties in the isolation from the normal brain, and in the in vitro expansion, have blocked preclinical and clinical study using aNSCs. However, several groups have recently developed novel techniques to isolate and expand aNSCs from normal adult brains, and showed successful applications of aNSCs to neurological diseases. With new technologies for aNSCs and their clinical strengths, previous hurdles in stem cell therapies for neurological diseases could be overcome, to realize clinically efficacious regenerative stem cell therapeutics.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The lack of curative therapies for neurodegenerative diseases has high economic impact and places huge burden on the society. The contribution of stem cells to cure neurodegenerative diseases has been unraveled and explored extensively over the past few years. Beyond substitution of the lost neurons, stem cells act as immunomodulators and neuroprotectors. A large number of preclinical and a small number of clinical studies have shown beneficial outcomes in this context. In this review, we have summarized the current concepts of stem cell therapy in neurodegenerative diseases and the recent advances in this field, particularly between 2010 and 2012. Further studies should be encouraged to resolve the clinical issues and vague translational findings for maximum optimization of the efficacy of stem cell therapy in neurodegenerative diseases.
    Neural Regeneration Research 08/2012; 7(23):1822-31. DOI:10.3969/j.issn.1673-5374.2012.23.009 · 0.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Highlights Transplants of hESC-DA survive long term and restore DA neurotransmission in vivo The functional potency of hESC-DA is similar to human fetal midbrain DA neurons hESC-DA are capable of long-distance, target-specific innerva-tion of the host brain The axonal outgrowth capacity of hESC-DA meets the require-ments for use in humans Authors In Brief Grealish et al. provide preclinical evi-dence that hESC-derived dopamine neu-rons are functionally equivalent to those derived from fetal tissue, supporting continued development of hESC-derived cells as a clinical approach for the treat-ment of Parkinson's disease.
    Cell Stem Cell 11/2014; 15(5):653-665. DOI:10.1016/j.stem.2014.09.017 · 22.15 Impact Factor

Full-text (2 Sources)

Available from
May 21, 2014